Car-t cell therapy for inflammatory bowel disease
Treatments studied
Part of Digestive system clinical trials.
This early-phase trial is testing a patient-specific immune cell therapy (called CAR-T) for people with active ulcerative colitis or Crohn's disease. The therapy targets two proteins on immune cells to help calm the inflammation in the gut.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old and have either ulcerative colitis or Crohn's disease.
- Your disease must be moderate to severe – meaning it's active despite previous treatment.
- You must have failed at least one standard treatment (like steroids or immunomodulators) or two different biologics (like infliximab or vedolizumab).
- Your heart, liver, kidneys, and blood counts need to be within acceptable ranges, and you must not have serious other illnesses (like cancer or heart failure).
- You must be willing to undergo tests like endoscopy and to stop certain other medicines before the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and BCMA, in people with autoimmune blood diseases like ITP, AIHA, or Evans syndrome that have not responded to standard treatments. It aims to reset the immune system and reduce production of harmful antibodies.
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
This trial tests a new treatment using modified immune cells (CAR-T cells) to reduce inflammation in people with moderate to severe inflammatory bowel disease (IBD) that hasn't improved with other advanced treatments.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
This trial tests a new treatment called RD06-05, which uses specially engineered immune cells to target and potentially reset parts of the immune system that are attacking your own body. It is being studied for several autoimmune conditions like lupus, vasculitis, kidney diseases, and more.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to calm down the immune attack that causes ulcerative colitis. It is for people with moderate to severe colitis who have not gotten better with standard medicines.
Hear when a new Moderate-to-severe Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.